8.18
前日終値:
$7.97
開ける:
$7.97
24時間の取引高:
2.91M
Relative Volume:
2.91
時価総額:
$396.93M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.5551
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+3.28%
1か月 パフォーマンス:
+38.88%
6か月 パフォーマンス:
-23.34%
1年 パフォーマンス:
-48.03%
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RGNX
Regenxbio Inc
|
8.18 | 396.93M | 89.04M | -241.08M | -194.72M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
2025-02-07 | 再開されました | Raymond James | Outperform |
2024-11-15 | 再開されました | Morgan Stanley | Overweight |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-06-07 | 開始されました | Goldman | Buy |
2024-03-11 | 開始されました | H.C. Wainwright | Buy |
2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-02-21 | 再開されました | Raymond James | Outperform |
2023-11-01 | 開始されました | Stifel | Buy |
2023-06-02 | 開始されました | Robert W. Baird | Outperform |
2022-06-23 | 開始されました | Berenberg | Buy |
2021-12-15 | 開始されました | Wedbush | Neutral |
2021-10-19 | 再開されました | Morgan Stanley | Overweight |
2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
2020-12-16 | 開始されました | UBS | Buy |
2020-06-25 | 再開されました | BofA/Merrill | Buy |
2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
2019-06-14 | 再開されました | Raymond James | Outperform |
2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
2018-05-09 | 繰り返されました | Barclays | Overweight |
2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
2018-02-13 | 開始されました | Mizuho | Neutral |
2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Australia
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - Seeking Alpha
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com
REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus
FDA sets review date for potential Hunter syndrome gene therapy - Investing.com Australia
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II - Stock Titan
Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance
Regenxbio Inc earnings missed by $0.36, revenue fell short of estimates - Investing.com India
REGENXBIO Reports Strong Q1 2025 Financial Results - TipRanks
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com South Africa
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights - Eagle-Tribune
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises - Investing.com Australia
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Regenxbio: Q1 Earnings Snapshot - San Antonio Express-News
REGENXBIO Inc. SEC 10-Q Report - TradingView
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
What to Expect from Regenxbio's Earnings - Nasdaq
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting - Citizen Tribune
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting | RGNX Stock News - GuruFocus
REGENXBIO to Participate in Upcoming Investor Conferences - Eagle-Tribune
REGENXBIO to Participate in Upcoming Investor Conferences | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - Citizen Tribune
REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth - simplywall.st
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus
REGENXBIO to Host Conference Call on May 12 to Discuss First Qua - GuruFocus
REGENXBIO Q1 2025 Earnings Call: Financial Results and Key Operations Update Coming May 12 - Stock Titan
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights | RGNX Stock News - GuruFocus
Investor Network: REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire
Regenxbio Inc’s Market Journey: Closing Weak at 5.93, Down -5.72 - DWinneX
REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC - Defense World
Form 8-KCurrent report - ADVFN
Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies - GuruFocus
Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria
RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa
When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com
Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia
Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):